Ong, M., Yeruva, S., Sailer, A., Nilsen, S
V.SeymourS
Analysis of CSF biomarkers revealed that IL-6 and GFAP levels increased from baseline to post-treatment, coinciding with a trending decrease in cytokines and chemokines associated with senescence
All products include Certificates of Analysis, ship domestically with appropriate cold chain protocols, and are priced in CAD
172,173 Significant benefits for obesity-associated diseases are also being reported (Table 5) including reduced heart failure events at 104 weeks of follow up (hazard ratio [HR] 0.62 compared to placebo), 110 improved management of obstructive sleep apnea at 52 weeks, 111 and improved management of metabolic-dysfunction associated steatohepatitis (MASH) with a decrease of 1 fibrosis stage with no worsening of MASH at 52 weeks